双歧杆菌DM-8504活菌制剂预防化疗引起的腹泻疗效观察  

PROPHALYXIS OF CHEMOTHERAPY-INDUCED DIARREA BY BIFIDOBACTERIUM AGENT

作　　者：刘基巍[1] 周涛[1] 张洁[1] 陈亚敏[1] 蔡欣[1] 

机构地区：[1]大连医科大学第一临床学院肿瘤科,辽宁大连116011

出　　处：《中国微生态学杂志》2000年第3期178-179,共2页Chinese Journal of Microecology

基　　金：省教委科题!双歧杆菌 DM- 85 0 4抗肿瘤临床作用

摘　　要：22例肿瘤化疗患者采用随机对照交叉试验 ,对照组采用单纯化疗实验组采用化疗 +双歧杆菌活菌制剂。结果显示双歧杆菌活菌制剂可预防化疗引起的腹泻 (对照组腹泻率 45 .5 % ,实验组为 2 7.3% ) ,并可改善腹泻的反应程度 (重度腹泻率对照组为 18.2 % ,实验组为 4.5 % ) ,有统计学差异 (P<0 .0 1) ,提示双歧杆菌活菌制剂预防化疗引起的腹泻疗效确切。cancer patients were auto-across-contrl randomised into test group (chemotherapy+Bifidobacterium agent), and control group (chemotherapy only). Prophalyxis of chemotherapy-induced diarrea by Bifidobacterium agent was effctive (diarrea 45.5% in control group, 27.3% in test group), and reduced grades of diarrea (heavy diarrea 18.2% in control group, 4.5 in test group), significantly different(P<0.01), indicating that Prophalyxis of chemotherapy-induced diarrea by Bifidobacterium agent was confirmed.

关 键 词：双歧杆菌 腹泻 DM-8504活菌制剂 预防 

分 类 号：R975.3[医药卫生—药品]